France · Delayed Price · Currency is EUR MaaT Pharma Statistics
Total Valuation
MaaT Pharma has a market cap or net worth of EUR 20.01 million. The enterprise value is 26.69 million.
| Market Cap | 20.01M |
| Enterprise Value | 26.69M |
Important Dates
The last earnings date was Tuesday, September 29, 2026.
| Earnings Date | Sep 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MaaT Pharma has 18.84 million shares outstanding. The number of shares has increased by 22.60% in one year.
| Current Share Class | 18.84M |
| Shares Outstanding | 18.84M |
| Shares Change (YoY) | +22.60% |
| Shares Change (QoQ) | +12.51% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 20.00% |
| Float | 11.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.30 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.36
| Current Ratio | 1.36 |
| Quick Ratio | 1.26 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.68 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -51.14% |
| Return on Invested Capital (ROIC) | -140.41% |
| Return on Capital Employed (ROCE) | -229.13% |
| Weighted Average Cost of Capital (WACC) | 6.46% |
| Revenue Per Employee | 52,933 |
| Profits Per Employee | -571,783 |
| Employee Count | 60 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.30% in the last 52 weeks. The beta is 0.62, so MaaT Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -75.30% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 38.19 |
| Average Volume (20 Days) | 101,296 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MaaT Pharma had revenue of EUR 3.18 million and -34.31 million in losses. Loss per share was -1.93.
| Revenue | 3.18M |
| Gross Profit | 2.13M |
| Operating Income | -33.98M |
| Pretax Income | -34.31M |
| Net Income | -34.31M |
| EBITDA | -30.65M |
| EBIT | -33.98M |
| Loss Per Share | -1.93 |
Balance Sheet
The company has 17.10 million in cash and 23.78 million in debt, with a net cash position of -6.67 million or -0.35 per share.
| Cash & Cash Equivalents | 17.10M |
| Total Debt | 23.78M |
| Net Cash | -6.67M |
| Net Cash Per Share | -0.35 |
| Equity (Book Value) | -16.22M |
| Book Value Per Share | -0.86 |
| Working Capital | 7.00M |
Cash Flow
In the last 12 months, operating cash flow was -15.54 million and capital expenditures -453,000, giving a free cash flow of -16.00 million.
| Operating Cash Flow | -15.54M |
| Capital Expenditures | -453,000 |
| Depreciation & Amortization | 3.34M |
| Net Borrowing | 9.45M |
| Free Cash Flow | -16.00M |
| FCF Per Share | -0.85 |
Margins
| Gross Margin | 67.16% |
| Operating Margin | -1,069.99% |
| Pretax Margin | -1,080.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MaaT Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.60% |
| Shareholder Yield | -22.60% |
| Earnings Yield | -181.44% |
| FCF Yield | -79.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for MaaT Pharma is 6.50, which is 512.05% higher than the current price. The consensus rating is "Buy".
| Price Target | 6.50 |
| Price Target Difference | 512.05% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 117.55% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaaT Pharma has an Altman Z-Score of -2.64 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 2 |